Slaughter and May is advising Reckitt Benckiser Group Plc (RB) on the demerger of its speciality pharmaceuticals business by way of transfer to Indivior Plc (Indivior), a company incorporated for the purposes of the demerger. Under the terms of the demerger, shareholders will receive shares in Indivior proportionate to their existing shareholding in RB. It is anticipated that Indivior will be listed on the main market of the London Stock Exchange.

RB is global consumer brands company headquartered in Slough, England. Indivior is a global pharmaceutical company specialising in the treatment of addiction and related mental health disorders.

CONTACTS

Corporate and Commercial: Jeff Twentyman (partner), Rebecca Cousin (partner), Henry Bennett (associate), James Bridges (associate), Graeme Earle (associate), Rahul Mehta (associate), Jamal Saleh (associate), Lomax Ward (associate); Corporate and Financing: Andrew McClean (partner), Thomas Coates (associate), Rebecca Nind (associate), Adrian Wilkes (associate); IP/IT: Susie Middlemiss (partner), Duncan Blaikie (associate), Mark Ellis (associate); Tax: Steve Edge (partner), Mike Lane (partner), George Mitchell (associate), Owen Williams (associate); Pensions and Employment: Roland Doughty (partner), Lucy Duane (associate); Real Estate and Environment: Jane Edwarde (partner), Rachael Ashton (associate)